BRAF and keratoacanthoma: Approximately 20% of patients treated with BRAF-inhibitor monotherapy will develop secondary skin tumors and other hyperproliferative lesions, such as squamous cell carcinoma (SCC) and keratoacanthomas (KA) [4].